Targeting NADPH oxidases in vascular pharmacology

Vascular Pharmacology

Volumn 56, Issue 5-6, 2012, Pages 216-231

  Schramm, Agata ^a   Matusik, Paweł ^a   Osmenda, Grzegorz ^a   Guzik, Tomasz J ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Endothelium; NADPH oxidase; Oxidative stress; Superoxide; Vascular

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPLERENONE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MINERALOCORTICOID RECEPTOR; PLUMBAGIN; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 3; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 5; RENIN INHIBITOR; SPIRONOLACTONE; UNCLASSIFIED DRUG; XANTHINE OXIDASE; ENZYME INHIBITOR; NITRIC OXIDE;

BIOAVAILABILITY; ENZYME ACTIVATION; ENZYME LOCALIZATION; ENZYME REGULATION; ENZYME STRUCTURE; ENZYME SYNTHESIS; HUMAN; MOLECULAR WEIGHT; NONHUMAN; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR BIOLOGY; ANIMAL; CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; NADPH OXIDASE; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84866183230     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.02.012     Document Type: Review

References (190)

1. Abe J., Berk B.C. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardiovasc. Med. 1998, 8:59-64.
2. Al Ghouleh I., Khoo N.K., Knaus U.G., Griendling K.K., Touyz R.M., Thannickal V.J., Barchowsky A., Nauseef W.M., Kelley E.E., Bauer P.M., Darley-Usmar V., Shiva S., Cifuentes-Pagano E., Freeman B.A., Gladwin M.T., Pagano P.J. Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. Free Radic. Biol. Med. 2011, 51:1271-1288.
3. Al-Awwadi N.A., Araiz C., Bornet A., Delbosc S., Cristol J.P., Linck N., Azay J., Teissedre P.L., Cros G. Extracts enriched in different polyphenolic families normalize increased cardiac NADPH oxidase expression while having differential effects on insulin resistance, hypertension, and cardiac hypertrophy in high-fructose-fed rats. J. Agric. Food Chem. 2005, 53:151-157.
4. Amanso A.M., Griendling K.K. Differential roles of NADPH oxidases in vascular physiology and pathophysiology. Front. Biosci. (Schol. Ed.) 2012, 4:1044-1064.
5. Ambasta R.K., Kumar P., Griendling K.K., Schmidt H.H., Busse R., Brandes R.P. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J. Biol. Chem. 2004, 279:45935-45941.
6. Anderson D., Phillips B.J. Comparative in vitro and in vivo effects of antioxidants. Food Chem. Toxicol. 1999, 37:1015-1025.
7. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 1995, 332:488-493.
8. Anon. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354:447-455.
9. Anon. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:23-33.
10. Antoniades C., Shirodaria C., Warrick N., Cai S., de Bono J., Lee J., Leeson P., Neubauer S., Ratnatunga C., Pillai R., Refsum H., Channon K.M. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006, 114:1193-1201.
11. Antoniades C., Bakogiannis C., Tousoulis D., Reilly S., Zhang M.H., Paschalis A., Antonopoulos A.S., Demosthenous M., Miliou A., Psarros C., Marinou K., Sfyras N., Economopoulos G., Casadei B., Channon K.M., Stefanadis C. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 2010, 122:S66-S73.
12. Antoniades C., Bakogiannis C., Leeson P., Guzik T.J., Zhang M.H., Tousoulis D., Antonopoulos A.S., Demosthenous M., Marinou K., Hale A., Paschalis A., Psarros C., Triantafyllou C., Bendall J., Casadei B., Stefanadis C., Channon K.M. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011, 124:335-345.
13. Antoniades C., Cunnington C., Antonopoulos A., Neville M., Margaritis M., Demosthenous M., Bendall J., Hale A., Cerrato R., Tousoulis D., Bakogiannis C., Marinou K., Toutouza M., Vlachopoulos C., Leeson P., Stefanadis C., Karpe F., Channon K.M. Induction of vascular GTP-cyclohydrolase I and endogenous tetrahydrobiopterin synthesis protect against inflammation-induced endothelial dysfunction in human atherosclerosis. Circulation 2011, 124:1860-1870.
14. Antoniades C., Demosthenous M., Reilly S., Margaritis M., Zhang M.H., Antonopoulos A., Marinou K., Nahar K., Jayaram R., Tousoulis D., Bakogiannis C., Sayeed R., Triantafyllou C., Koumallos N., Psarros C., Miliou A., Stefanadis C., Channon K.M., Casadei B. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J. Am. Coll. Cardiol. 2012, 59:60-70.
15. Azen S.P., Qian D., Mack W.J., Sevanian A., Selzer R.H., Liu C.R., Liu C.H., Hodis H.N. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation 1996, 94:2369-2372.
16. Badimon L., Vilahur G., Padro T. Nutraceuticals and atherosclerosis: human trials. Cardiovasc. Ther. 2010, 28:202-215.
17. Banfi B., Molnar G., Maturana A., Steger K., Hegedus B., Demaurex N., Krause K.H. A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes. J. Biol. Chem. 2001, 276:37594-37601.
18. Banfi B., Malgrange B., Knisz J., Steger K., Dubois-Dauphin M., Krause K.H. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J. Biol. Chem. 2004, 279:46065-46072.
19. Bao X.M., Wu C.F., Lu G.P. Atorvastatin inhibits homocysteine-induced oxidative stress and apoptosis in endothelial progenitor cells involving Nox4 and p38MAPK. Atherosclerosis 2010, 210:114-121.
20. Bauersachs J., Widder J.D. Endothelial dysfunction in heart failure. Pharmacol. Rep. 2008, 60:119-126.
21. Bayorh M.A., Rollins-Hairston A., Adiyiah J., Lyn D., Eatman D. Eplerenone suppresses aldosterone/ salt-induced expression of NOX-4. J. Renin Angiotensin Aldosterone Syst. 2011, 12:195-201.
22. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007, 87:245-313.
23. BelAiba R.S., Djordjevic T., Petry A., Diemer K., Bonello S., Banfi B., Hess J., Pogrebniak A., Bickel C., Gorlach A. NOX5 variants are functionally active in endothelial cells. Free Radic. Biol. Med. 2007, 42:446-459.
24. Berry C., Hamilton C.A., Brosnan M.J., Magill F.G., Berg G.A., McMurray J.J., Dominiczak A.F. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000, 101:2206-2212.
25. Biasucci L.M., Biasillo G., Stefanelli A. Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clin. Chem. Lab. Med. 2010, 48:1685-1691.
26. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007, 297:842-857.
27. Blair A., Shaul P.W., Yuhanna I.S., Conrad P.A., Smart E.J. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J. Biol. Chem. 1999, 274:32512-32519.
28. Boaz M., Smetana S., Weinstein T., Matas Z., Gafter U., Iaina A., Knecht A., Weissgarten Y., Brunner D., Fainaru M., Green M.S. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000, 356:1213-1218.
29. Briones A.M., Tabet F., Callera G.E., Montezano A.C., Yogi A., He Y., Quinn M.T., Salaices M., Touyz R.M. Differential regulation of Nox1, Nox2 and Nox4 in vascular smooth muscle cells from WKY and SHR. J. Am. Soc. Hypertens. 2011, 5:137-153.
30. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001, 345:1583-1592.
31. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
32. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 2000, 87:840-844.
33. Cayatte A.J., Rupin A., Oliver-Krasinski J., Maitland K., Sansilvestri-Morel P., Boussard M.F., Wierzbicki M., Verbeuren T.J., Cohen R.A. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1577-1584.
34. Celermajer D.S., Sorensen K.E., Bull C., Robinson J., Deanfield J.E. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J. Am. Coll. Cardiol. 1994, 24:1468-1474.
35. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
36. Clempus R.E., Sorescu D., Dikalova A.E., Pounkova L., Jo P., Sorescu G.P., Schmidt H.H., Lassegue B., Griendling K.K. Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler. Thromb. Vasc. Biol. 2007, 27:42-48.
37. Cook N.R., Albert C.M., Gaziano J.M., Zaharris E., MacFadyen J., Danielson E., Buring J.E., Manson J.E. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch. Intern. Med. 2007, 167:1610-1618.
38. Cosentino F., Barker J.E., Brand M.P., Heales S.J., Werner E.R., Tippins J.R., West N., Channon K.M., Volpe M., Luscher T.F. Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2001, 21:496-502.
39. Cui W., Matsuno K., Iwata K., Ibi M., Katsuyama M., Kakehi T., Sasaki M., Ikami K., Zhu K., Yabe-Nishimura C. NADPH oxidase isoforms and anti-hypertensive effects of atorvastatin demonstrated in two animal models. J. Pharmacol. Sci. 2009, 111:260-268.
40. Dal-Ros S., Oswald-Mammosser M., Pestrikova T., Schott C., Boehm N., Bronner C., Chataigneau T., Geny B., Schini-Kerth V.B. Losartan prevents portal hypertension-induced, redox-mediated endothelial dysfunction in the mesenteric artery in rats. Gastroenterology 2010, 138:1574-1584.
41. De Deken X., Wang D., Many M.C., Costagliola S., Libert F., Vassart G., Dumont J.E., Miot F. Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. J. Biol. Chem. 2000, 275:23227-23233.
42. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001, 357:89-95.
43. Despres J.P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 2005, 353:2121-2134.
44. Diatchuk V., Lotan O., Koshkin V., Wikstroem P., Pick E. Inhibition of NADPH oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related compounds. J. Biol. Chem. 1997, 272:13292-13301.
45. Dikalov S.I., Dikalova A.E., Bikineyeva A.T., Schmidt H.H., Harrison D.G., Griendling K.K. Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic. Biol. Med. 2008, 45:1340-1351.
46. Doughan A.K., Harrison D.G., Dikalov S.I. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ. Res. 2008, 102:488-496.
47. Drummond G.R., Selemidis S., Griendling K.K., Sobey C.G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 2011, 10:453-471.
48. Efimova O., Szankasi P., Kelley T.W. Ncf1 (p47phox) is essential for direct regulatory T cell mediated suppression of CD4+ effector T cells. PLoS One 2011, 6:e16013.
49. Engels F., Renirie B.F., Hart B.A., Labadie R.P., Nijkamp F.P. Effects of apocynin, a drug isolated from the roots of Picrorhiza kurroa, on arachidonic acid metabolism. FEBS Lett. 1992, 305:254-256.
50. Ennezat P.V., Vannesson C., Bouabdallaoui N., Marechaux S., Asseman P., LeJemtel T.H. Imagine how many lives you save: angiotensin-converting enzyme inhibition for atherosclerotic vascular disease in the present era of risk reduction. Expert Opin. Pharmacother. 2011, 12:883-897.
51. Fan Y.Y., Kohno M., Nakano D., Hitomi H., Nagai Y., Fujisawa Y., Lu X.M., Fu H., Du J., Ohmori K., Hosomi N., Kimura S., Kiyomoto H., Nishiyama A. Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats. J. Hypertens. 2009, 27:1855-1862.
52. Fang J.C., Kinlay S., Beltrame J., Hikiti H., Wainstein M., Behrendt D., Suh J., Frei B., Mudge G.H., Selwyn A.P., Ganz P. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 2002, 359:1108-1113.
53. Fukuda M., Nakamura T., Kataoka K., Nako H., Tokutomi Y., Dong Y.F., Ogawa H., Kim-Mitsuyama S. Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice. J. Hypertens. 2010, 28:340-352.
54. Gallin J.I., Leto T.L., Rotrosen D., Kwong C.H., Malech H.L. Delineation of the phagocyte NADPH oxidase through studies of chronic granulomatous diseases of childhood. Curr. Opin. Immunol. 1992, 4:53-56.
55. Gao L., Mann G.E. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc. Res. 2009, 82:9-20.
56. Gazdikova K., Gvozdjakova A., Kucharska J., Spustova V., Braunova Z., Dzurik R. Malondialdehyde and selected antioxidant plasma levels in conservatively treated patients with kidney diseases. Bratisl. Lek. Listy 2000, 101:490-494.
57. Ghosh M., Wang H.D., McNeill J.R. Role of oxidative stress and nitric oxide in regulation of spontaneous tone in aorta of DOCA-salt hypertensive rats. Br. J. Pharmacol. 2004, 141:562-573.
58. Gongora M.C., Lob H.E., Landmesser U., Guzik T.J., Martin W.D., Ozumi K., Wall S.M., Wilson D.S., Murthy N., Gravanis M., Fukai T., Harrison D.G. Loss of extracellular superoxide dismutase leads to acute lung damage in the presence of ambient air: a potential mechanism underlying adult respiratory distress syndrome. Am. J. Pathol. 2008, 173:915-926.
59. Greenberg E.R., Baron J.A., Karagas M.R., Stukel T.A., Nierenberg D.W., Stevens M.M., Mandel J.S., Haile R.W. Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. JAMA 1996, 275:699-703.
60. Griendling K.K., FitzGerald G.A. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003, 108:1912-1916.
61. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994, 74:1141-1148.
62. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 2000, 86:494-501.
63. Gryglewski R.J., Palmer R.M., Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986, 320:454-456.
64. Gutterman D.D. Vascular dysfunction in hyperglycemia: is protein kinase C the culprit?. Circ. Res. 2002, 90:5-7.
65. Guzik T.J., Griendling K.K. NADPH oxidases: molecular understanding finally reaching the clinical level?. Antioxid. Redox Signal. 2009, 11:2365-2370.
66. Guzik T.J., Harrison D.G. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov. Today 2006, 11:524-533.
67. Guzik T.J., Harrison D.G. Endothelial NF-kappaB as a mediator of kidney damage: the missing link between systemic vascular and renal disease?. Circ. Res. 2007, 101:227-229.
68. Guzik T.J., West N.E., Black E., McDonald D., Ratnatunga C., Pillai R., Channon K.M. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000, 102:1744-1747.
69. Guzik T.J., West N.E., Black E., McDonald D., Ratnatunga C., Pillai R., Channon K.M. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ. Res. 2000, 86:E85-E90.
70. Guzik T.J., Mussa S., Gastaldi D., Sadowski J., Ratnatunga C., Pillai R., Channon K.M. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002, 105:1656-1662.
71. Guzik T.J., West N.E., Pillai R., Taggart D.P., Channon K.M. Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels. Hypertension 2002, 39:1088-1094.
72. Guzik T.J., Olszanecki R., Sadowski J., Kapelak B., Rudzinski P., Jopek A., Kawczynska A., Ryszawa N., Loster J., Jawien J., Czesnikiewicz-Guzik M., Channon K.M., Korbut R. Superoxide dismutase activity and expression in human venous and arterial bypass graft vessels. J. Physiol. Pharmacol. 2005, 56:313-323.
73. Guzik T.J., Sadowski J., Guzik B., Jopek A., Kapelak B., Przybylowski P., Wierzbicki K., Korbut R., Harrison D.G., Channon K.M. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2006, 26:333-339.
74. Guzik T.J., Hoch N.E., Brown K.A., McCann L.A., Rahman A., Dikalov S., Goronzy J., Weyand C., Harrison D.G. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 2007, 204:2449-2460.
75. Guzik T.J., Chen W., Gongora M.C., Guzik B., Lob H.E., Mangalat D., Hoch N., Dikalov S., Rudzinski P., Kapelak B., Sadowski J., Harrison D.G. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J. Am. Coll. Cardiol. 2008, 52:1803-1809.
76. Guzik B., Chwala M., Matusik P., Ludew D., Skiba D., Wilk G., Mrowiecki W., Batko B., Cencora A., Kapelak B., Sadowski J., Korbut R., Guzik T.J. Mechanisms of increased vascular superoxide production in human varicose veins. Pol. Arch. Med. Wewn. 2011, 121:279-286.
77. Halliwell B. The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 1993, 23(Suppl. 1):118-126.
78. Hamilton C.A., Brosnan M.J., Al-Benna S., Berg G., Dominiczak A.F. NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension 2002, 40:755-762.
79. Harel Z., Gilbert C., Wald R., Bell C., Perl J., Juurlink D., Beyene J., Shah P.S. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 2012, 344:e42.
80. Harrison D., Griendling K.K., Landmesser U., Hornig B., Drexler H. Role of oxidative stress in atherosclerosis. Am. J. Cardiol. 2003, 91:7A-11A.
81. Harrison D.G., Gongora M.C., Guzik T.J., Widder J. Oxidative stress and hypertension. J. Am. Soc. Hypertens. 2007, 1:30-44.
82. Heeschen C., Jang J.J., Weis M., Pathak A., Kaji S., Hu R.S., Tsao P.S., Johnson F.L., Cooke J.P. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat. Med. 2001, 7:833-839.
83. Heitzer T., Schlinzig T., Krohn K., Meinertz T., Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104:2673-2678.
84. Hennekens C.H., Buring J.E., Manson J.E., Stampfer M., Rosner B., Cook N.R., Belanger C., LaMotte F., Gaziano J.M., Ridker P.M., Willett W., Peto R. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 1996, 334:1145-1149.
85. Heo S.K., Yun H.J., Noh E.K., Park S.D. Emodin and rhein inhibit LIGHT-induced monocytes migration by blocking of ROS production. Vascul. Pharmacol. 2010, 53:28-37.
86. Heumuller S., Wind S., Barbosa-Sicard E., Schmidt H.H., Busse R., Schroder K., Brandes R.P. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008, 51:211-217.
87. Hodis H.N., Mack W.J., LaBree L., Mahrer P.R., Sevanian A., Liu C.R., Liu C.H., Hwang J., Selzer R.H., Azen S.P., Grp V.R. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis - The Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 2002, 106:1453-1459.
88. Husain K., Suarez E., Isidro A., Ferder L. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am. J. Nephrol. 2010, 32:296-304.
89. Inanaga K., Ichiki T., Miyazaki R., Takeda K., Hashimoto T., Matsuura H., Sunagawa K. Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice. Atherosclerosis 2010, 213:52-58.
90. Irani K. Oxidant signaling in vascular cell growth, death, and survival : a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ. Res. 2000, 87:179-183.
91. Iwai M., Kanno H., Inaba S., Senba I., Sone H., Nakaoka H., Horiuchi M. Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. Am. J. Hypertens. 2011, 24:169-174.
92. Jackson S.H., Devadas S., Kwon J., Pinto L.A., Williams M.S. T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat. Immunol. 2004, 5:818-827.
93. Jones D.P. Redefining oxidative stress. Antioxid. Redox Signal. 2006, 8:1865-1879.
94. Kamioka M., Ishibashi T., Sugimoto K., Uekita H., Nagai R., Sakamoto N., Ando K., Ohkawara H., Teramoto T., Maruyama Y., Takeishi Y. Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways. J. Atheroscler. Thromb. 2010, 17:590-600.
95. Katsiki N., Manes C. Is there a role for supplemented antioxidants in the prevention of atherosclerosis?. Clin. Nutr. 2009, 28:3-9.
96. Kim J.A., Neupane G.P., Lee E.S., Jeong B.S., Park B.C., Thapa P. NADPH oxidase inhibitors: a patent review. Expert Opin. Ther. Pat. 2011, 21:1147-1158.
97. Kregel K.C., Zhang H.J. An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292:R18-R36.
98. Kunsch C., Medford R.M. Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res. 1999, 85:753-766.
99. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., Mitch W.E., Harrison D.G. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 2003, 111:1201-1209.
100. Lapperre T.S., Jimenez L.A., Antonicelli F., Drost E.M., Hiemstra P.S., Stolk J., MacNee W., Rahman I. Apocynin increases glutathione synthesis and activates AP-1 in alveolar epithelial cells. FEBS Lett. 1999, 443:235-239.
101. Laurent E., McCoy J.W., Macina R.A., Liu W., Cheng G., Robine S., Papkoff J., Lambeth J.D. Nox1 is over-expressed in human colon cancers and correlates with activating mutations in K-Ras. Int. J. Cancer 2008, 123:100-107.
102. Lee W.J., Ou H.C., Hsu W.C., Chou M.M., Tseng J.J., Hsu S.L., Tsai K.L., Sheu W.H. Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells. J. Vasc. Surg. 2010, 52:1290-1300.
103. Leto T.L., Morand S., Hurt D., Ueyama T. Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. Antioxid. Redox Signal. 2009, 11:2607-2619.
104. Liu J., Zhou J., An W., Lin Y., Yang Y., Zang W. Apocynin attenuates pressure overload-induced cardiac hypertrophy in rats by reducing levels of reactive oxygen species. Can. J. Physiol. Pharmacol. 2010, 88:745-752.
105. Lob H.E., Marvar P.J., Guzik T.J., Sharma S., McCann L.A., Weyand C., Gordon F.J., Harrison D.G. Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension 2010, 55:277-283. (276p following 283).
106. Lonn E., Yusuf S., Hoogwerf B., Pogue J., Yi Q., Zinman B., Bosch J., Dagenais G., Mann J.F., Gerstein H.C. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002, 25:1919-1927.
107. Lyle A.N., Griendling K.K. Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology (Bethesda) 2006, 21:269-280.
108. Madamanchi N.R., Runge M.S. NADPH oxidases and atherosclerosis: unraveling the details. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1-H2.
109. Madhur M.S., Lob H.E., McCann L.A., Iwakura Y., Blinder Y., Guzik T.J., Harrison D.G. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010, 55:500-507.
110. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J.C., Najib-Fruchart J., Glineur C., Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J. Clin. Invest. 2001, 107:1423-1432.
111. Massenet C., Chenavas S., Cohen-Addad C., Dagher M.C., Brandolin G., Pebay-Peyroula E., Fieschi F. Effects of p47phox C terminus phosphorylations on binding interactions with p40phox and p67phox. Structural and functional comparison of p40phox and p67phox SH3 domains. J. Biol. Chem. 2005, 280:13752-13761.
112. Micheletta F., Natoli S., Misuraca M., Sbarigia E., Diczfalusy U., Iuliano L. Vitamin E supplementation in patients with carotid atherosclerosis: reversal of altered oxidative stress status in plasma but not in plaque. Arterioscler. Thromb. Vasc. Biol. 2004, 24:136-140.
113. Miguel-Carrasco J.L., Zambrano S., Blanca A.J., Mate A., Vazquez C.M. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J. Inflamm. (Lond.) 2010, 7:21.
114. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005, 142:37-46.
115. Montezano A.C., Touyz R.M. Reactive oxygen species and endothelial function-role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic Clin. Pharmacol. Toxicol. 2012, 110:87-94.
116. Morawietz H. Endothelial NADPH oxidases: friends or foes?. Basic Res. Cardiol. 2011, 106:521-525.
117. Morawietz H., Weber M., Rueckschloss U., Lauer N., Hacker A., Kojda G. Upregulation of vascular NAD(P)H oxidase subunit gp91phox and impairment of the nitric oxide signal transduction pathway in hypertension. Biochem. Biophys. Res. Commun. 2001, 285:1130-1135.
118. Muller G., Morawietz H. Nitric oxide, NAD(P)H oxidase, and atherosclerosis. Antioxid. Redox Signal. 2009, 11:1711-1731.
119. Munzel T., Kurz S., Rajagopalan S., Thoenes M., Berrington W.R., Thompson J.A., Freeman B.A., Harrison D.G. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J. Clin. Invest. 1996, 98:1465-1470.
120. Munzel T., Gori T., Bruno R.M., Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease?. Eur. Heart J. 2010, 31:2741-2748.
121. Mythri R.B., Venkateshappa C., Harish G., Mahadevan A., Muthane U.B., Yasha T.C., Srinivas Bharath M.M., Shankar S.K. Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem. Res. 2011, 36:1452-1463.
122. Nicholls S.J., Hazen S.L. The role of myeloperoxidase in the pathogenesis of coronary artery disease. Jpn. J. Infect. Dis. 2004, 57:S21-S22.
123. Ohmine T., Miwa Y., Takahashi-Yanaga F., Morimoto S., Maehara Y., Sasaguri T. The involvement of aldosterone in cyclic stretch-mediated activation of NADPH oxidase in vascular smooth muscle cells. Hypertens. Res. 2009, 32:690-699.
124. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., Keogh J.P., Meyskens F.L., Valanis B., Williams J.H., Barnhart S., Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 1996, 334:1150-1155.
125. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 2007, 87:315-424.
126. Pagano P.J., Chanock S.J., Siwik D.A., Colucci W.S., Clark J.K. Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. Hypertension 1998, 32:331-337.
127. Piette J., Piret B., Bonizzi G., Schoonbroodt S., Merville M.P., Legrand-Poels S., Bours V. Multiple redox regulation in NF-kappaB transcription factor activation. Biol. Chem. 1997, 378:1237-1245.
128. Poss J., Werner C., Lorenz D., Gensch C., Bohm M., Laufs U. The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice. Basic Res. Cardiol. 2010, 105:725-735.
129. Powell S.B., Sejnowski T.J., Behrens M.M. Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuronmaturation in rodent models of schizophrenia. Neuropharmacology 2012, 62(3):1322-1331.
130. Rada B., Leto T.L. Oxidative innate immune defenses by Nox/Duox family NADPH oxidases. Contrib. Microbiol. 2008, 15:164-187.
131. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K., Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 1996, 97:1916-1923.
132. Rapola J.M., Virtamo J., Haukka J.K., Heinonen O.P., Albanes D., Taylor P.R., Huttunen J.K. Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial. JAMA 1996, 275:693-698.
133. Ray R., Shah A.M. NADPH oxidase and endothelial cell function. Clin. Sci. (Lond.) 2005, 109:217-226.
134. Ray R., Murdoch C.E., Wang M., Santos C.X., Zhang M., Alom-Ruiz S., Anilkumar N., Ouattara A., Cave A.C., Walker S.J., Grieve D.J., Charles R.L., Eaton P., Brewer A.C., Shah A.M. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1368-1376.
135. Rey F.E., Cifuentes M.E., Kiarash A., Quinn M.T., Pagano P.J. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ. Res. 2001, 89:408-414.
136. Rhee S.G., Bae Y.S., Lee S.R., Kwon J. Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. Sci. STKE 2000, 2000:pe1.
137. Rhee S.G., Chang T.S., Bae Y.S., Lee S.R., Kang S.W. Cellular regulation by hydrogen peroxide. J. Am. Soc. Nephrol. 2003, 14:S211-S215.
138. Rucker D., Padwal R., Li S.K., Curioni C., Lau D.C. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007, 335:1194-1199.
139. Rueckschloss U., Galle J., Holtz J., Zerkowski H.R., Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 2001, 104:1767-1772.
140. Rueckschloss U., Quinn M.T., Holtz J., Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1845-1851.
141. Ryszawa N., Kawczynska-Drozdz A., Pryjma J., Czesnikiewicz-Guzik M., Adamek-Guzik T., Naruszewicz M., Korbut R., Guzik T.J. Effects of novel plant antioxidants on platelet superoxide production and aggregation in atherosclerosis. J. Physiol. Pharmacol. 2006, 57:611-626.
142. Salonen J.T., Nyyssonen K., Salonen R., Lakka H.M., Kaikkonen J., Porkkala-Sarataho E., Voutilainen S., Lakka T.A., Rissanen T., Leskinen L., Tuomainen T.P., Valkonen V.P., Ristonmaa U., Poulsen H.E. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J. Intern. Med. 2000, 248:377-386.
143. Sancho P., Fabregat I. The NADPH oxidase inhibitor VAS2870 impairs cell growth and enhances TGF-beta-induced apoptosis of liver tumor cells. Biochem. Pharmacol. 2011, 81:917-924.
144. Sarna L.K., Wu N., Hwang S.Y., Siow Y.L., O K. Berberine inhibits NADPH oxidase mediated superoxide anion production in macrophages. Can. J. Physiol. Pharmacol. 2010, 88:369-378.
145. Sartorio C.L., Fraccarollo D., Galuppo P., Leutke M., Ertl G., Stefanon I., Bauersachs J. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension 2007, 50:919-925.
146. Sasaki T., Kuzuya M., Nakamura K., Cheng X.W., Hayashi T., Song H., Hu L., Okumura K., Murohara T., Iguchi A., Sato K. AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice. Atherosclerosis 2010, 210:430-437.
147. Sedeek M., Callera G., Montezano A., Gutsol A., Heitz F., Szyndralewiez C., Page P., Kennedy C.R., Burns K.D., Touyz R.M., Hebert R.L. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2010, 299:F1348-F1358.
148. Selemidis S., Sobey C.G., Wingler K., Schmidt H.H., Drummond G.R. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol. Ther. 2008, 120:254-291.
149. Shaerzadeh F., Ahmadiani A., Esmaeili M.A., Ansari N., Asadi S., Tusi S.K., Sonboli A., Ghahremanzamaneh M., Khodagholi F. Antioxidant and antiglycating activities of Salvia sahendica and its protective effect against oxidative stress in neuron-like PC12 cells. J. Nat. Med. 2011, 65:455-465.
150. Shi J., Ross C.R., Leto T.L., Blecha F. PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:6014-6018.
151. Singh R.B., Niaz M.A., Rastogi S.S., Rastogi S. Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3). Am. J. Cardiol. 1996, 77:232-236.
152. Sorescu D., Weiss D., Lassegue B., Clempus R.E., Szocs K., Sorescu G.P., Valppu L., Quinn M.T., Lambeth J.D., Vega J.D., Taylor W.R., Griendling K.K. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002, 105:1429-1435.
153. Steckert A.V., Valvassori S.S., Moretti M., Dal-Pizzol F., Quevedo J. Role of oxidative stress in the pathophysiology of bipolar disorder. Neurochem. Res. 2010, 35:1295-1301.
154. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781-786.
155. Stolk J., Hiltermann T.J., Dijkman J.H., Verhoeven A.J. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am. J. Respir. Cell Mol. Biol. 1994, 11:95-102.
156. Streeter J., Thiel W., Brieger K., Miller F.J. Opportunity Nox: The Future of NADPH Oxidases as Therapeutic Targets in Cardiovascular Disease. Cardiovasc. Ther 2012, doi:10.1111/j.1755-5922.2011.00310.x. [Epub ahead of print].
157. Szuldrzynski K., Zalewski J., Machnik A., Zmudka K. Elevated levels of 8-iso-prostaglandin F2alpha in acute coronary syndromes are associated with systemic and local platelet activation. Pol. Arch. Med. Wewn. 2010, 120:19-24.
158. Takac I., Schroder K., Zhang L., Lardy B., Anilkumar N., Lambeth J.D., Shah A.M., Morel F., Brandes R.P. The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J. Biol. Chem. 2011, 286:13304-13313.
159. Takac I., Schroder K., Brandes R.P. The nox family of NADPH oxidases: friend or foe of the vascular system?. Curr. Hypertens. Rep. 2012, 14:70-78.
160. Takai S., Jin D., Ikeda H., Sakonjo H., Miyazaki M. Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats. Hypertens. Res. 2009, 32:853-860.
161. Takai S., Jin D., Kawashima H., Kimura M., Shiraishi-Tateishi A., Tanaka T., Kakutani S., Tanaka K., Kiso Y., Miyazaki M. Anti-atherosclerotic effects of dihomo-gamma-linolenic acid in ApoE-deficient mice. J. Atheroscler. Thromb. 2009, 16:480-489.
162. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1712-1719.
163. Tam J., Vemuri V.K., Liu J., Batkai S., Mukhopadhyay B., Godlewski G., Osei-Hyiaman D., Ohnuma S., Ambudkar S.V., Pickel J., Makriyannis A., Kunos G. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J. Clin. Invest. 2010, 120:2953-2966.
164. Tardif J.C., Cote G., Lesperance J., Bourassa M., Lambert J., Doucet S., Bilodeau L., Nattel S., de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N. Engl. J. Med. 1997, 337:365-372.
165. ten Freyhaus H., Huntgeburth M., Wingler K., Schnitker J., Baumer A.T., Vantler M., Bekhite M.M., Wartenberg M., Sauer H., Rosenkranz S. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc. Res. 2006, 71:331-341.
166. Tesfamariam B., Brown M.L., Deykin D., Cohen R.A. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J. Clin. Invest. 1990, 85:929-932.
167. Tiyerili V., Zimmer S., Jung S., Wassmann K., Naehle C.P., Lutjohann D., Zimmer A., Nickenig G., Wassmann S. CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res. Cardiol. 2010, 105:465-477.
168. Traber M.G., Stevens J.F. Vitamins C and E: beneficial effects from a mechanistic perspective. Free Radic. Biol. Med. 2011, 51:1000-1013.
169. Tsunekawa T., Hayashi T., Kano H., Sumi D., Matsui-Hirai H., Thakur N.K., Egashira K., Iguchi A. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001, 104:376-379.
170. Van Gaal L., Pi-Sunyer X., Despres J.P., McCarthy C., Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008, 31(Suppl. 2):S229-S240.
171. Van Gaal L.F., Scheen A.J., Rissanen A.M., Rossner S., Hanotin C., Ziegler O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur. Heart J. 2008, 29:1761-1771.
172. Vasquez-Vivar J., Kalyanaraman B., Martasek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radic. Res. 2003, 37:121-127.
173. Virdis A., Neves M.F., Amiri F., Viel E., Touyz R.M., Schiffrin E.L. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002, 40:504-510.
174. Virtamo J., Rapola J.M., Ripatti S., Heinonen O.P., Taylor P.R., Albanes D., Huttunen J.K. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch. Intern. Med. 1998, 158:668-675.
175. von Lohneysen K., Noack D., Jesaitis A.J., Dinauer M.C., Knaus U.G. Mutational analysis reveals distinct features of the Nox4-p22 phox complex. J. Biol. Chem. 2008, 283:35273-35282.
176. Warnholtz A., Nickenig G., Schulz E., Macharzina R., Brasen J.H., Skatchkov M., Heitzer T., Stasch J.P., Griendling K.K., Harrison D.G., Bohm M., Meinertz T., Munzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999, 99:2027-2033.
177. Wassmann S., Laufs U., Muller K., Konkol C., Ahlbory K., Baumer A.T., Linz W., Bohm M., Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 2002, 22:300-305.
178. Waters D.D., Alderman E.L., Hsia J., Howard B.V., Cobb F.R., Rogers W.J., Ouyang P., Thompson P., Tardif J.C., Higginson L., Bittner V., Steffes M., Gordon D.J., Proschan M., Younes N., Verter J.I. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002, 288:2432-2440.
179. Widder J.D., Harrison D.G. Can vitamin E prevent cardiovascular events and cancer?. Nat. Clin. Pract. Cardiovasc. Med. 2005, 2:510-511.
180. Wind S., Beuerlein K., Eucker T., Muller H., Scheurer P., Armitage M.E., Ho H., Schmidt H.H., Wingler K. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br. J. Pharmacol. 2010, 161:885-898.
181. Wingler K., Hermans J.J., Schiffers P., Moens A., Paul M., Schmidt H.H. NOX1, 2, 4, 5: counting out oxidative stress. Br. J. Pharmacol. 2011, 164:866-883.
182. Xu S., Jiang B., Hou X., Shi C., Bachschmid M.M., Zang M., Verbeuren T.J., Cohen R.A. High-fat diet increases and the polyphenol, S17834, decreases acetylation of the sirtuin-1-dependent lysine-382 on p53 and apoptotic signaling in atherosclerotic lesion-prone aortic endothelium of normal mice. J. Cardiovasc. Pharmacol. 2011, 58:263-271.
183. Yagi S., Akaike M., Aihara K., Ishikawa K., Iwase T., Ikeda Y., Soeki T., Yoshida S., Sumitomo-Ueda Y., Matsumoto T., Sata M. Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury. Hypertension 2010, 55:918-923.
184. Yamamoto E., Kataoka K., Dong Y.F., Nakamura T., Fukuda M., Tokutomi Y., Matsuba S., Nako H., Nakagata N., Kaneko T., Ogawa H., Kim-Mitsuyama S. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 2009, 54:633-638.
185. Yamamoto E., Kataoka K., Dong Y.F., Nakamura T., Fukuda M., Nako H., Ogawa H., Kim-Mitsuyama S. Benidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats. J. Hypertens. 2010, 28:1321-1329.
186. Yao K.S., Xanthoudakis S., Curran T., O'Dwyer P.J. Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol. Cell. Biol. 1994, 14:5997-6003.
187. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000, 342:154-160.
188. Zhang H., Schmeisser A., Garlichs C.D., Plotze K., Damme U., Mugge A., Daniel W.G. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc. Res. 1999, 44:215-222.
189. Zhang L.N., Gamo Y., Sinclair R., Mitchell S.E., Morgan D.G., Clapham J.C., Speakman J.R. Effects of Chronic Oral Rimonabant Administration on Energy Budgets of Diet-Induced Obese C57BL/6 Mice. Obesity (Silver Spring) 2011, doi:10.1038/oby.2011.357. [Epub ahead of print].
190. Zureik M., Galan P., Bertrais S., Mennen L., Czernichow S., Blacher J., Ducimetiere P., Hercberg S. Effects of long-term daily low-dose supplementation with antioxidant vitamins and minerals on structure and function of large arteries. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1485-1491.